Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS.
about
Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant VirusNovel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014).Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.
P2860
Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Optimization of the antiviral ...... a novel class of HIV-1 NNRTIS.
@ast
Optimization of the antiviral ...... a novel class of HIV-1 NNRTIS.
@en
type
label
Optimization of the antiviral ...... a novel class of HIV-1 NNRTIS.
@ast
Optimization of the antiviral ...... a novel class of HIV-1 NNRTIS.
@en
prefLabel
Optimization of the antiviral ...... a novel class of HIV-1 NNRTIS.
@ast
Optimization of the antiviral ...... a novel class of HIV-1 NNRTIS.
@en
P2093
P2860
P356
P1433
P1476
Optimization of the antiviral ...... a novel class of HIV-1 NNRTIS
@en
P2093
Bingjie Qin
Chin Ho Chen
Keduo Qian
Kuo-Hsiung Lee
Susan L Morris-Natschke
Zhi-Yuan Wu
P2860
P304
P356
10.1002/CMDC.201400075
P577
2014-06-04T00:00:00Z